Nitroimidazoles as anti-tumor agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 687-691

  Liu, Kai ^a   Zhu, Hai Liang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

2 nitroimidazole; Anti tumor; Bio reductive prodrug; Hypoxic cell radiosensitizer

Indexed keywords

1 [4 [3 (2 NITROIMIDAZOLYL) PROPYLAMINO] 7 CHLOROQUINOLINE]; 1,2 DICARBA CLOSO DODECABORANE; ANTINEOPLASTIC AGENT; BORANE DERIVATIVE; KIN 806; KIN 841; MISONIDAZOLE; N1 (2 HYDROXYETHYL) N 1 METHYL 2 (2 NITRO 1H 11 IMIDAZOLYL)ACETAMIDE; N1,N1 DIMETHYL 2 (2 NITRO 1H 1 IMIDAZOLYL)ACETAMIDE; NITROIMIDAZOLE; RADIOSENSITIZING AGENT; TX 1877; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BINDING AFFINITY; CANCER INHIBITION; CLINICAL TRIAL (TOPIC); DOWN REGULATION; DRUG ACTIVITY; DRUG DNA BINDING; DRUG MECHANISM; HUMAN; HYPOXIC CELL; LUNG METASTASIS; NEUROTOXICITY; NEUTRON CAPTURE THERAPY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

EID: 80051747292     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011796817664     Document Type: Review

References (35)

1. Jemal, A.; Siegel, R.; Xu, J.Q.; Ward, E. Cancer Statistics, 2010. CA Cancer. J. Clin., 2010, 60, 277-300.
2. Johnson, J.R.; Bross, P.; Cohen, M.; Rothmann, M.; Chen, G.; Zajicek, A.; Gobburu, J.; Rahman, A.; Staten, A.; Pazdur, R. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase. Clin. Cancer Res., 2003, 9, 1972-1979.
3. Dancey, J.E.; Freidlin, B. Targeting epidermal growth factor receptor- are we missing the mark? Lancet, 2003, 362, 62-64.
4. Mital, A. Synthetic Nitroimidazoles: Biological Activities and Mutagenicity Relationships. Sci. Pharm., 2009, 77, 497-520.
5. Gunay, N.S.; Capan, G.; Ulusoy, N.; Ergenc, N.; Otuk G.; Kaya, D. Nitroimidazole derivatives as possible antibacterial and antifungal agents. Farmaco., 1999, 54, 826-831.
6. Cavalleri, B.; Ballotta, R.; Arioli, V.; Lancini, G. New 5- substituted 1-alkyl-2-nitroimidazoles. J. Med. Chem., 1973, 16, 557-560.
7. Silvestri, R.; Artico, M.; De Martino, G.; Ragno, R.; Massa, S.; Loddo, R.; Murgioni, C.; Loi, A.G.; La Colla, P.; Pani, A. Synthesis, biological evaluation, and binding mode of novel 1-[2- (diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptase. J. Med. Chem., 2002, 45, 1567-1576.
8. Paulson, O.B.; Melgaard, B.; Hansen, H.S.; Kamieniecka, Z.; Kohler, O.; Hansen, J.M.; Pedersen, A.G.; Tang, X.; Trojaborg, W. Misonidazole neuropathy. Acta. Neurol. Scand. (Suppl.), 1984, 100, 133-135.
9. Qian, Y.; Zhang, H.J.; Zhang, H.; Xu, C.; Zhao, J.; Zhu, H.L. Synthesis, molecular modeling, and biological evaluation of cinnamic acid metronidazole ester derivatives as novel anticancer agents. Bioorg. Med. Chem., 2010, 18, 4991-4996.
10. Wardman, P. The use of nitroaromatic compounds as hypoxic cell radiosensitizers. Curr. Top. Radiat. Res. Q., 1977, 11, 347-398.
11. Kasai, S.; Nagasawa, H.; Yamashita, M.; Masui, M.; Kuwasaka, H.; Oshodani, T.; Uto, Y.; Inomata, T.; Oka, S.; Inayama, S.; Hori, H. New antimetastatic hypoxic cell radiosensitizers: design, synthesis, and biological activities of 2-nitroimidazole-acetamide, TX-1877, and its analogues. Bioorg. Med. Chem., 2001, 9, 453-464.
12. Papadopoulou, M.V.; Ji, M.; Rao, M.K.; Bloomer, W.D. 4-[3-(2- Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine. Oncol. Res., 2000, 12, 185-189.
13. Reid, J.M.; Squillace, D.P.; Ames, M.M. Single-dosepharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC709257) in CD2F1 mice. Cancer. Chem. Pharm., 2003, 51, 483-487.
14. Breider, M.A.; Pilcher, G.D.; Graziano, M.J.; Gough, A.W. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol. Pathol., 1998, 26, 234-239.
15. Denny, W.A. The role of hypoxia-activated prodrugs in cancer therapy. Lancet. Oncol., 2000, 1, 25-29.
16. Shweiki, D.; Itin, A.; Soffer, D.; Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992, 359, 843-845.
17. Shimamura, M.; Nagasawa, H.; Ashino, H.; Yamamoto, Y.; Hazato, T.; Uto, Y.; Hori Inayama, H. S. A novel hypoxiadependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors. Br. J. Cancer., 2003, 88, 307-313.
18. Koike, H.; Hori, H.; Inayama, S.; Terada, H. Effect of arylidenecyclopentenedione radiosensitizers on ATP synthesis in mitochondria: action as potent inhibitors of phosphate transport. Biochem. Biophys. Res. Commun., 1988, 155, 1066-1074.
19. Hori, H.; Nagasawa, H.; Uto, Y.; Ohkura, K.; Kirk, K.L.; Uehara, Y.; Shimamura, M. Design of hypoxia-targeting protein tyrosine kinase inhibitor using an innovative pharmacophore 2-methylene- 4-cyclopentene-1,3-dione. Biochim. Biophys. Acta., 2004, 1697, 29-38.
20. Lesnikowski, Z.J.; Olejniczak, A.; In: ESF EMRC Exploratory Workshop on BioBor-Exploring New Opportunities of Boron Chemistry Towards Medicine, Lodz, Poland, May 9-12, 2008;
21. Threadgill, M.D.; Medicinal Chemistry, Department of Pharmacy & Pharmacology, University of Bath: Claverton, UK, 2008, pp. 119-130.
22. Brown, J.M.; Giaccia, A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer. Res. 1998, 58, 1405-16.
23. Baish, J.W.; Netti, P.A.; Jain, R.K. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc. Res. 1997, 53, 128-141.
24. Toffoli, S.; Michiels, C. Intermittent hypoxia is a key regulator of cancer cell and Endothelial cell interplay in tumours. FEBS. Journal. 2008, 275, 2991-3002.
25. Graeber, T.G.; Osmanian, C.; Jacks, T.; Housman, D.E.; Koch, C.J.; Lowe, S.W.; Giaccia, A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 1996, 379, 88-91.
26. Cosse, J.P.; Sermeus, A.; Vannuvel, K.; Ninane, N.; Raes, M.; Michiels, C. Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol. Cancer, 2007, 6, 61-76.
27. Lee, S.M.; Lee, C.T.; Kim, Y.W.; Han, S.K.; Shim, Y.S.; Yoo, C.G. Hypoxia confers protection against apoptosis via PI3K Akt and ERK pathways in lung cancer cells. Cancer. Lett, 2006, 242, 231-238.
28. Merighi, S.; Benini, A.; Mirandola, P.; Gessi, S.; Varani, K.; Leung, E.; Maclennan, S.; Baraldi, P.G.; Borea, P.A. Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol. Pharmacol. 2007, 72, 162-172.
29. Moeller, B.J.; Richardson, R.A.; Dewhirst, M.W. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer. Metastasis. Rev., 2007, 26, 241-248.
30. Piret, J.P.; Lecocq, C.; Toffoli, S.; Ninane, N.; Raes, M.; Michiels, C. Hypoxia and CoCl2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp. Cell. Res., 2004, 295, 340-349.
31. Schnitzer, S.E.; Schmid, T.; Zhou, J.; Brune, B. Hypoxia and HIF-1 alpha protect A549 cells from drug-induced apoptosis. Cell. Death. Differ. 2006, 13, 1611-1613.
32. Song, X.; Liu, X.; Chi, W.; Liu, Y.; Wei, L.; Wang, X.; Yu, J. Hypoxia-induced resistance to cisplatin and doxorubicin in nonsmall cell lung cancer is inhibited by silencing of HIF-1 alpha gene. Cancer. Chem. Pharm. 2006, 58, 776-784.
33. Wardman, P.; Phys. J. Reduction potentials of one-electron couples involving free radicals in aqueous solution. Chem. Ref. Data. 1989, 18, 1664-1667.
34. 99mTc(CO)3 complexes to target hypoxic tumors. J. Label Compd. Radiopharm. 2010, 53, 535-554.
35. Kondoh, S.K.; Nagasawa, H.K. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer. Sci., 2009, 100, 1366-1373.